Cargando…
Novel Bioactivity of Ellagic Acid in Inhibiting Human Platelet Activation
Pomegranates are widely consumed either as fresh fruit or in beverage form as juice and wine. Ellagic acid possesses potent antioxidative properties; it is known to be an effective phytotherapeutic agent with antimutagenic and anticarcinogenic qualities. Ellagic acid (20 to 80 μM) exhibited a potent...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3594952/ https://www.ncbi.nlm.nih.gov/pubmed/23533502 http://dx.doi.org/10.1155/2013/595128 |
_version_ | 1782262367180029952 |
---|---|
author | Chang, Yi Chen, Wei-Fan Lin, Kuan-Hung Hsieh, Cheng-Ying Chou, Duen-Suey Lin, Li-Jyun Sheu, Joen-Rong Chang, Chao-Chien |
author_facet | Chang, Yi Chen, Wei-Fan Lin, Kuan-Hung Hsieh, Cheng-Ying Chou, Duen-Suey Lin, Li-Jyun Sheu, Joen-Rong Chang, Chao-Chien |
author_sort | Chang, Yi |
collection | PubMed |
description | Pomegranates are widely consumed either as fresh fruit or in beverage form as juice and wine. Ellagic acid possesses potent antioxidative properties; it is known to be an effective phytotherapeutic agent with antimutagenic and anticarcinogenic qualities. Ellagic acid (20 to 80 μM) exhibited a potent activity in inhibiting platelet aggregation stimulated by collagen; however, it did not inhibit platelet aggregation stimulated by thrombin, arachidonic acid, or U46619. Treatment with ellagic acid (50 and 80 μM) significantly inhibited platelet activation stimulated by collagen; this alteration was accompanied by the inhibition of relative [Ca(2+)](i) mobilization, and the phosphorylation of phospholipase C (PLC)γ2, protein kinase C (PKC), mitogen-activated protein kinases (MAPKs), and Akt, as well as hydroxyl radical (OH(●)) formation. In addition, ellagic acid also inhibited p38 MAPK and Akt phosphorylation stimulated by hydrogen peroxide. By contrast, ellagic acid did not significantly affect PKC activation and platelet aggregation stimulated by PDBu. This study is the first to show that, in addition to being considered a possible agent for preventing tumor growth, ellagic acid possesses potent antiplatelet properties. It appears to initially inhibit the PLCγ2-PKC cascade and/or hydroxyl radical formation, followed by decreased phosphorylation of MAPKs and Akt, ultimately inhibiting platelet aggregation. |
format | Online Article Text |
id | pubmed-3594952 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | Hindawi Publishing Corporation |
record_format | MEDLINE/PubMed |
spelling | pubmed-35949522013-03-26 Novel Bioactivity of Ellagic Acid in Inhibiting Human Platelet Activation Chang, Yi Chen, Wei-Fan Lin, Kuan-Hung Hsieh, Cheng-Ying Chou, Duen-Suey Lin, Li-Jyun Sheu, Joen-Rong Chang, Chao-Chien Evid Based Complement Alternat Med Research Article Pomegranates are widely consumed either as fresh fruit or in beverage form as juice and wine. Ellagic acid possesses potent antioxidative properties; it is known to be an effective phytotherapeutic agent with antimutagenic and anticarcinogenic qualities. Ellagic acid (20 to 80 μM) exhibited a potent activity in inhibiting platelet aggregation stimulated by collagen; however, it did not inhibit platelet aggregation stimulated by thrombin, arachidonic acid, or U46619. Treatment with ellagic acid (50 and 80 μM) significantly inhibited platelet activation stimulated by collagen; this alteration was accompanied by the inhibition of relative [Ca(2+)](i) mobilization, and the phosphorylation of phospholipase C (PLC)γ2, protein kinase C (PKC), mitogen-activated protein kinases (MAPKs), and Akt, as well as hydroxyl radical (OH(●)) formation. In addition, ellagic acid also inhibited p38 MAPK and Akt phosphorylation stimulated by hydrogen peroxide. By contrast, ellagic acid did not significantly affect PKC activation and platelet aggregation stimulated by PDBu. This study is the first to show that, in addition to being considered a possible agent for preventing tumor growth, ellagic acid possesses potent antiplatelet properties. It appears to initially inhibit the PLCγ2-PKC cascade and/or hydroxyl radical formation, followed by decreased phosphorylation of MAPKs and Akt, ultimately inhibiting platelet aggregation. Hindawi Publishing Corporation 2013 2013-02-21 /pmc/articles/PMC3594952/ /pubmed/23533502 http://dx.doi.org/10.1155/2013/595128 Text en Copyright © 2013 Yi Chang et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Chang, Yi Chen, Wei-Fan Lin, Kuan-Hung Hsieh, Cheng-Ying Chou, Duen-Suey Lin, Li-Jyun Sheu, Joen-Rong Chang, Chao-Chien Novel Bioactivity of Ellagic Acid in Inhibiting Human Platelet Activation |
title | Novel Bioactivity of Ellagic Acid in Inhibiting Human Platelet Activation |
title_full | Novel Bioactivity of Ellagic Acid in Inhibiting Human Platelet Activation |
title_fullStr | Novel Bioactivity of Ellagic Acid in Inhibiting Human Platelet Activation |
title_full_unstemmed | Novel Bioactivity of Ellagic Acid in Inhibiting Human Platelet Activation |
title_short | Novel Bioactivity of Ellagic Acid in Inhibiting Human Platelet Activation |
title_sort | novel bioactivity of ellagic acid in inhibiting human platelet activation |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3594952/ https://www.ncbi.nlm.nih.gov/pubmed/23533502 http://dx.doi.org/10.1155/2013/595128 |
work_keys_str_mv | AT changyi novelbioactivityofellagicacidininhibitinghumanplateletactivation AT chenweifan novelbioactivityofellagicacidininhibitinghumanplateletactivation AT linkuanhung novelbioactivityofellagicacidininhibitinghumanplateletactivation AT hsiehchengying novelbioactivityofellagicacidininhibitinghumanplateletactivation AT chouduensuey novelbioactivityofellagicacidininhibitinghumanplateletactivation AT linlijyun novelbioactivityofellagicacidininhibitinghumanplateletactivation AT sheujoenrong novelbioactivityofellagicacidininhibitinghumanplateletactivation AT changchaochien novelbioactivityofellagicacidininhibitinghumanplateletactivation |